PIK3CA Mutations Negatively Affect Survival in Trastuzumab-Treated HER2-Positive Breast Cancer
A study confirmed that PIK3CA mutations negatively affect survival in patients with HER2-positive breast cancer treated with the anti-HER2 therapy trastuzumab. (Source: Cancer Network)
Source: Cancer Network - May 6, 2013 Category: Cancer & Oncology Source Type: news

Implementing a Comprehensive Infection-Prevention Plan
Nurses from a New Jersey cancer center have adapted several key plans from the CDC, ONS, and other societies to create a comprehensive infection-control plan. (Source: Cancer Network)
Source: Cancer Network - May 6, 2013 Category: Cancer & Oncology Source Type: news

Axitinib Fails to Improve Survival in Metastatic Colorectal Cancer
Adding the VEGF inhibitor axitinib to first-line treatment of FOLFOX-6 for metastatic colorectal cancer failed to improve progression-free and overall survival. (Source: Cancer Network)
Source: Cancer Network - May 6, 2013 Category: Cancer & Oncology Source Type: news

AML Genome Reveals Complexities, Potential Driver Mutations
Researchers have characterized acute myeloid leukemia, providing new genetic driver leads to help classify the disease and even stratify AML patients by risk. (Source: Cancer Network)
Source: Cancer Network - May 5, 2013 Category: Cancer & Oncology Source Type: news

I Can’t Talk to You With a Gun in My Face
How many times have you been killed for being the messenger with the bad news? You can often tell who is going to be angry when the CT scan shows recurrent disease. It is one of many things that are so stressful about being an oncologist. Let’s be honest; over the course of our career, we give a lot of bad news. (Source: Cancer Network)
Source: Cancer Network - May 3, 2013 Category: Cancer & Oncology Source Type: news

FDA Panel Votes 'No' on Tivozanib for Renal Cancer
The FDA’s Oncologic Drugs Advisory Committee has voted 13 to 1 against AVEO's drug tivozanib for the treatment of patients with metastatic renal cell carcinoma. (Source: Cancer Network)
Source: Cancer Network - May 3, 2013 Category: Cancer & Oncology Source Type: news

“This Is My Last Day on Earth”
To my oncologist: You certainly were pleasant and compassionate. You also tended to minimize the gravity of the situation when my disease progressed. I know you’re not psychic, but when things are going badly, don’t be afraid to tell me you’re worried. (Source: Cancer Network)
Source: Cancer Network - May 2, 2013 Category: Cancer & Oncology Source Type: news

Secondary Cancer Risk Found With Multiple Myeloma Maintenance Therapies
Multiple myeloma patients are at increased risk of developing myelodysplastic syndrome or acute leukemia after maintenance lenalidomide or thalidomide treatment, according to a new study. (Source: Cancer Network)
Source: Cancer Network - May 2, 2013 Category: Cancer & Oncology Source Type: news

Novel Agents Now Prevalent Method of Care for Multiple Myeloma
A majority of patients with multiple myeloma are being treated with novel agents such as thalidomide, bortezomib, and lenalidomide within a year of diagnosis instead of the chemotherapeutic regimens that were more prevalent a decade ago, according to a new study. (Source: Cancer Network)
Source: Cancer Network - May 2, 2013 Category: Cancer & Oncology Source Type: news

Are CML Drugs Priced Out of Reach?
A group of experts say that cancer drug prices, especially those for chronic myeloid leukemia, have skyrocketed, making patient treatment extremely difficult. (Source: Cancer Network)
Source: Cancer Network - May 2, 2013 Category: Cancer & Oncology Source Type: news

HER2-Targeted Therapies Could Benefit Lung Cancer Patients With HER2 Mutations
A new study shows that drugs targeting HER2 might provide good results in the rare non-small-cell lung cancer (NSCLC) patients with HER2 mutations. (Source: Cancer Network)
Source: Cancer Network - May 1, 2013 Category: Cancer & Oncology Source Type: news

US Cancer Organizations Say Medicare Cuts Will Negatively Impact Cancer Patients
Four of the nation’s cancer organizations--including the COA and ASCO--believe that the sequestration cuts will impact the treatment of cancer patients on Medicare and have sent letters to Congress and the Department of Health and Human Services. (Source: Cancer Network)
Source: Cancer Network - May 1, 2013 Category: Cancer & Oncology Source Type: news

ONS: Safe Handling of Chemotherapy
Oncology nurses from a community hospital in Cincinnati, Ohio implemented a two-pronged process for the safe handling of chemotherapy, improving nurses’ satisfaction and comfort levels regarding chemotherapy safety. (Source: Cancer Network)
Source: Cancer Network - April 29, 2013 Category: Cancer & Oncology Source Type: news

ONS: Nurse-Physician PACT Yields Sharp Decrease in Codes
A team of nurses and physicians from Huntsman Cancer Institute successfully implemented key changes in their Patient Acute Change Team that increased nurse involvement and reduced the number of codes by 90% in the outpatient setting since they were put in place 2 years ago. (Source: Cancer Network)
Source: Cancer Network - April 29, 2013 Category: Cancer & Oncology Source Type: news

ONS: Infection Risk, Prevention, and Management
In this interview, Laura Zitella will be discussing challenges and considerations for management and prevention of infection in the oncology setting—in both patients with solid tumors and those with hematologic malignancies. (Source: Cancer Network)
Source: Cancer Network - April 29, 2013 Category: Cancer & Oncology Source Type: news

Oncologists Hope Congress Will Exempt Cancer Drugs From Sequester Cuts
Oncologists hit by sequester budget cuts to the cost of purchasing and administering cancer drugs are hoping that the potentially devastating impact on Medicare cancer patients will force a quick legislative fix in Congress. (Source: Cancer Network)
Source: Cancer Network - April 27, 2013 Category: Cancer & Oncology Source Type: news

ONS: Genetics and Genomics Matters
This interview covers standards for healthcare provider competency in offering comprehensive genetic services, and highlighting genetics/genomics resources for nurses. (Source: Cancer Network)
Source: Cancer Network - April 26, 2013 Category: Cancer & Oncology Source Type: news

ONS: Holistic Nursing Interventions Reduced Patient Anxiety, Nausea, and Pain During Hospitalization or RT Treatments
A holistic nursing interventions study, presented at the ONS Congress, highlights its ability to reduce anxiety, nausea, and pain, and improve select vital signs. (Source: Cancer Network)
Source: Cancer Network - April 26, 2013 Category: Cancer & Oncology Source Type: news

ONS: Health IT as a Tool for Improved, Patient-Centric Care
The integration of information technology into healthcare—such as EHRs and patient portals—is growing by leaps and bounds, and cancer care is no exception. Judy Murphy from HHS provides important perspectives on this topic. (Source: Cancer Network)
Source: Cancer Network - April 26, 2013 Category: Cancer & Oncology Source Type: news

A 47-Year-Old Patient With Chronic Abdominal Pain
A 47-year-old male with complaints of chronic abdominal pain and episodes of flushing presents for evaluation. What is your diagnosis? (Source: Cancer Network)
Source: Cancer Network - April 26, 2013 Category: Cancer & Oncology Source Type: news

Groups Issue New Social Media Guidelines for Physicians
New guidelines make recommendations on how physicians should conduct themselves online, examining the effect of Facebook and Twitter on patient-physician relationships. (Source: Cancer Network)
Source: Cancer Network - April 26, 2013 Category: Cancer & Oncology Source Type: news

Prostate Cancer Risk Higher in Obese Men After Benign Biopsy
A case-control study of almost 500 men suggests that obese men who have had a benign prostate biopsy have a greater risk of prostate cancer in the future. (Source: Cancer Network)
Source: Cancer Network - April 26, 2013 Category: Cancer & Oncology Source Type: news

Osteopontin Identified as Potential New Target in Treatment of ALL
Targeting the bone marrow–specific extracellular matrix osteopontin may be an effective strategy to increase the efficacy of chemotherapy in patients with acute lymphocytic leukemia, according to the authors of a recent study. (Source: Cancer Network)
Source: Cancer Network - April 24, 2013 Category: Cancer & Oncology Source Type: news

US Task Force Recommends Breast Cancer Medications for High-Risk Women
The US Preventive Services Task Force, an influential panel of experts, said that women at high risk for breast cancer should consider taking breast cancer drugs to decrease their risk. (Source: Cancer Network)
Source: Cancer Network - April 24, 2013 Category: Cancer & Oncology Source Type: news

ONS: Understanding Spirituality and How It Can Be Used to Help Patients
In this interview, Tami Borneman, who is presenting a poster at the 38th Annual ONS Congress, will discuss spirituality: what it means, and how spiritual interventions can benefit patients with cancer (Source: Cancer Network)
Source: Cancer Network - April 24, 2013 Category: Cancer & Oncology Source Type: news

EPOCH-Rituximab Therapy Obviates Need for Radiotherapy in B-Cell Lymphoma
A dose-adjusted regimen of etoposide, doxorubicin, and cyclophosphamide with vincristine, prednisone, and rituximab (DA-EPOCH-R) obviated the need for radiotherapy in patients with primary mediastinal B-cell lymphoma in a single-group, phase II, prospective study. (Source: Cancer Network)
Source: Cancer Network - April 23, 2013 Category: Cancer & Oncology Source Type: news

NSCLC Patient Develops Erythema After Vancomycin Infusion
A 71-year-old man with a smoking history of more than 100 pack-years developed non–small-cell carcinoma of the lung. During his an infusion of vancomycin he developed flushing, followed by widespread fixed erythema, muscular spasms in the back, and transient but severe hypotension. Can he ever receive vancomycin again? (Source: Cancer Network)
Source: Cancer Network - April 22, 2013 Category: Cancer & Oncology Source Type: news

In Mouse Model, Imaging Strategy Follows Prostate Cancer Bone Metastasis Response to Cabozantinib
A mouse model of bone metastasis can be used to follow real-time response to therapeutics in preclinical development, such as cabozantinib, according to results presented in the poster session of the 2013 AACR annual meeting. (Source: Cancer Network)
Source: Cancer Network - April 22, 2013 Category: Cancer & Oncology Source Type: news

Endometrial Cancer at Young Age Ups Risk for Colorectal Cancer
Women diagnosed with endometrial cancer at age 50 or younger had a fourfold increased risk for a subsequent colorectal cancer diagnosis, according to a historical cohort study published recently in the Journal of Clinical Oncology. (Source: Cancer Network)
Source: Cancer Network - April 22, 2013 Category: Cancer & Oncology Source Type: news

Small Kidney Tumors Potentially Dangerous, Worth Treating
Even those renal cell carcinomas (RCCs) that are smaller than 4 cm may put patients at risk for aggressive cancer, according to a new study presented at the 28th Annual European Association of Urology Congress in Milan, Italy. (Source: Cancer Network)
Source: Cancer Network - April 22, 2013 Category: Cancer & Oncology Source Type: news

Zoledronic Acid Did Not Prevent Bone Metastases in High-Risk Prostate Cancer
The use of zoledronic acid (Zometa) had no effect on the prevention of bone metastases in patients with high-risk prostate cancer, according to the first results of the Zometa European Study, or ZEUS, presented at the European Association of Urology 28th Annual Congress in Milan, Italy. (Source: Cancer Network)
Source: Cancer Network - April 18, 2013 Category: Cancer & Oncology Source Type: news

Serum Assay Composed of Trio of Biomarkers May Help Detect Kidney Cancers
A new immunoassay that tests for the presence of nicotinamide N-methyltransferase (NNMT), L-plastin (LCP1), and nonmetastatic cells 1 protein (NM23A) may be an effective method for the early detection of malignant kidney cancer. (Source: Cancer Network)
Source: Cancer Network - April 18, 2013 Category: Cancer & Oncology Source Type: news

Chronic Fatigue Limits Quality of Life in Imatinib-Treated CML Patients
A study of patients with chronic myeloid leukemia treated with imatinib found that chronic fatigue is the major factor that limits health-related quality of life. (Source: Cancer Network)
Source: Cancer Network - April 17, 2013 Category: Cancer & Oncology Source Type: news

Value Judgments in Diagnostic Imaging for Prostate Cancer: A Paradox in Healthcare Reform
Only the possibility of increasing survival with better tumor localization and staging is probable with multiparametric MRI—and improved survival with MR imaging in prostate cancer has not been shown in a clinical trial or meta-analysis to date. (Source: Cancer Network)
Source: Cancer Network - April 15, 2013 Category: Cancer & Oncology Source Type: news

Treatment Recommendations for Anaplastic Oligodendrogliomas That Are Codeleted
Although important questions still remain regarding chemotherapy choice, sequence, and dosing, the answers to which will require additional large phase III trials, radiotherapy alone is no longer appropriate therapy for 1p/19q codeleted anaplastic oligodendrogliomas. (Source: Cancer Network)
Source: Cancer Network - April 15, 2013 Category: Cancer & Oncology Source Type: news

The State of Prostate MRI in 2013
Our aims in this article are to describe the various imaging sequences that comprise the multiparametric MRI exam, as well as to review current literature on the strengths/weaknesses of these sequences; to delineate strategies for standardizing interpretation and reporting of MRI results; and to expound on the role of prostate MRI in clinical practice. (Source: Cancer Network)
Source: Cancer Network - April 15, 2013 Category: Cancer & Oncology Source Type: news

Recurrent Epithelial Ovarian Cancer: An Update on Treatment
Emerging therapies in the management of ovarian cancer have resulted in a shift in paradigm, including in the appropriate time to institute therapy, and in the selection of therapy. This review focuses on chemotherapy and emerging biologic agents that present a therapeutic option for patients with recurrent ovarian cancer. (Source: Cancer Network)
Source: Cancer Network - April 15, 2013 Category: Cancer & Oncology Source Type: news

Accelerated Partial-Breast Irradiation: The Current State of Our Knowledge
Accelerated partial-breast irradiation is a shorter, alternative radiation technique for select patients with favorable early-stage breast cancer. We review here the different modalities of delivery and discuss the possible benefits and harms associated with these treatments. (Source: Cancer Network)
Source: Cancer Network - April 15, 2013 Category: Cancer & Oncology Source Type: news

Financial Toxicity, Part II: How Can We Help With the Burden of Treatment-Related Costs?
Just as high-quality research has focused on limiting the physical toxicity resulting from successful treatment, future research should focus on mitigating the negative effects of financial toxicity without affecting disease-related outcomes. (Source: Cancer Network)
Source: Cancer Network - April 15, 2013 Category: Cancer & Oncology Source Type: news

Novel Tumor Suppressor Identified for Prostate Cancer
Researchers have identified the enzyme PKCζ, which acts as a tumor suppressor in prostate cancer and is part of a pathway that partly controls cell growth and metastasis. (Source: Cancer Network)
Source: Cancer Network - April 15, 2013 Category: Cancer & Oncology Source Type: news

Long-Term Treatment With Imatinib Affected Bone Mineral Density
A majority of patients on imatinib for treatment of GIST or CML had low or absent levels of osteocalcin, a bone marker secreted by osteoblasts, and about 50% of patients had a decrease in bone mineral density, signaling that long-term treatment may affect bone health in these patients. (Source: Cancer Network)
Source: Cancer Network - April 15, 2013 Category: Cancer & Oncology Source Type: news

Smoking Linked to Poorer Prognosis in Colon Cancer
Patients with stage III colon cancer who have a history of smoking are more likely to have worse outcomes, according to a large, randomized phase III trial result. (Source: Cancer Network)
Source: Cancer Network - April 13, 2013 Category: Cancer & Oncology Source Type: news

Patient Quality of Life Endpoints in Oncology Trials, Part II
This interview covers symptom management and quality-of-life outcomes in cancer clinical trials, which are being incorporated more readily as secondary and sometimes primary trial endpoints. (Source: Cancer Network)
Source: Cancer Network - April 12, 2013 Category: Cancer & Oncology Source Type: news

Nilotinib for CML Leads to Fewer Treatment-Emergent Mutations Than Imatinib
CML patients treated with nilotinib had fewer treatment-emergent BCR-ABL mutations than those treated with imatinib, and among patients who did have a mutation, those treated with nilotinib had reduced rates of progression to accelerated phase and blast phase of the disease. (Source: Cancer Network)
Source: Cancer Network - April 12, 2013 Category: Cancer & Oncology Source Type: news

AACR: Developmental Signaling Takes the Front Stage
The Wnt signaling pathway was demonstrated as a promising target in cancer stem cell therapy through a series of talks highlighting the promise and efficacy of a new generation of inhibitors that are making their way into the clinic. (Source: Cancer Network)
Source: Cancer Network - April 11, 2013 Category: Cancer & Oncology Source Type: news

AACR: Pan-AKT Inhibitor ARQ092 Shows Promise in Solid Tumors in First-in-Human Trial
The pan-AKT inhibitor ARQ092 was shown to be well-tolerated, avoiding dose-limiting toxicities that often haunt inhibitors of AKT signaling, according to results presented at the 2013 AACR meeting. (Source: Cancer Network)
Source: Cancer Network - April 11, 2013 Category: Cancer & Oncology Source Type: news

AACR: Results of THYME Trial Show the Time Is Not Right for AZD8931
The THYME trial testing AZD8931 in advanced HER2-low breast cancer failed to reach the primary endpoint of progression-free survival, according to results of the phase II trial presented at the 2013 AACR meeting in Washington, DC. (Source: Cancer Network)
Source: Cancer Network - April 11, 2013 Category: Cancer & Oncology Source Type: news

AACR: Immunotherapy Antibody Has Activity in Range of Solid Tumors
The anti-PD-L1 antibody MPDL3280A is effective for several different cancers and was well tolerated. Responses were seen in lung, kidney, colon, and stomach cancer patients. All patients who responded are continuing to respond to the treatment. (Source: Cancer Network)
Source: Cancer Network - April 10, 2013 Category: Cancer & Oncology Source Type: news

Smoking Immediately After Waking Correlates With Higher Carcinogen Levels
The faster one smokes a cigarette after waking in the morning, the higher the biologic exposure to an important tobacco-related carcinogen, according to a new study. Time to first cigarette, or TTFC, could be a useful marker of high lung cancer risk among smokers as a result. (Source: Cancer Network)
Source: Cancer Network - April 9, 2013 Category: Cancer & Oncology Source Type: news

Estrogen, Progestin Use Linked to Increased Breast Cancer Incidence
The use of estrogen plus progestin in postmenopausal women has once again been linked to an increased risk for breast cancer, according to the results from a Women’s Health Initiative observational cohort study, especially among women who initiated hormone therapy closer to menopause. (Source: Cancer Network)
Source: Cancer Network - April 9, 2013 Category: Cancer & Oncology Source Type: news